Synagistics Limited — Board/Management Information 2021

Dec 29, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [63 x 86] intentionally omitted <==

WEALTHKING INVESTMENTS LIMITED 華 科 資 本 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board (the ‘‘Board’’) of directors (the ‘‘Director(s)’’) of Wealthking Investments Limited (the ‘‘Company’’) announces that due to personal reasons, Dr. Zhu Xianzhong (‘‘Dr. Zhu’’) ceased to be the chief executive officer of the Company effective 29 December 2021.

Dr. Zhu has confirmed that he has no disagreement with the Board and that there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (‘‘Stock Exchange’’). The Board would like to take this opportunity to express its sincere gratitude to Dr. Zhu for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Dr. Liu Zhiwei (‘‘Dr. Liu’’), an executive Director of the Company and the chairman of the Board, will be appointed as the chief executive officer with effect from 29 December 2021.

Dr. Liu, aged 54, has been appointed as Chairman of the Board and the Chairman of the Nomination Committee since 16 December 2020, and an executive Director of the Company since 16 April 2019. From 16 April 2019 to 16 December 2020, he was the chief executive officer of the Company. From June 2016 to June 2018, he was an executive Director, the president of the Company, and a member of the corporate governance committee. From December 2015 to June 2016, he served as a non-executive director of the Company. Currently, Dr. Liu also serves as the director of various subsidiaries of the Company.

– 1 –

Dr. Liu obtained a bachelor’s degree in Industrial Management Engineering from Zhe Jiang University in 1989. He furthered his studies in Graduate School of the People’s Bank of China between 1989 and 1992 and obtained his master’s degree in international finance. In 2007, he obtained a doctoral degree in Economics & Law from Hunan University. Dr. Liu completed a professional programme in Finance CEO from Cheung Kong Graduate School of Business in 2010.

Dr. Liu has over 20 years of experience in financing, securities investment and capital market. He served as a non-executive director of Shanghai Zendai Property Limited (stock code: 755), whose shares are listed on Stock Exchange for the period from 2 February 2010 to 12 December 2012. He was the vice chairman of Chang’an International Trust Co., Ltd (formerly known as Xi’an International Trust Co., Ltd) from 2008 to 2011. Dr. Liu served as a supervisor of Xin Jiang Hui-tong (Group) Co., Ltd (stock code: 415) from December 2005 to December 2008, whose shares are listed on the Shenzhen Stock Exchange. He also served as a general manager of the merger and acquisition department of Guosen Securities Co., Ltd from 1997 to 1998.

The Company has entered into a service contract with Dr. Liu pursuant to which the term of appointment of Dr. Liu shall be three years which may be terminated by one month’s prior notice in writing served by either party on the other. There is no additional remuneration payable to Dr. Liu for acting as the chief executive officer of the Company.

Save as disclosed above, Dr. Liu (i) does not have any relationship with any director, senior management, substantial or controlling shareholder (having the meaning ascribed to it in the Rules Governing the Listing of Securities on the Stock Exchange (‘‘Listing Rules’’)) of the Company; (ii) does not hold any other positions in the Company or its subsidiaries; and (iii) did not hold any directorships in the past three years in other listed public companies the securities of which are listed on any securities market in Hong Kong or overseas.

As at the date of this announcement, Dr. Liu is beneficially interested in 431,066,000 shares in the Company (representing approximately 10.61% of the issued shares of the Company). Save as the aforesaid, Dr. Liu does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Other than the above, there is no other matter in relation to the appointment of Dr. Liu as the chief executive officer that needs to be brought to the attention of the shareholders of the Company, nor is there any information that should be disclosed pursuant to any of the requirements of Rule 13.51 (2) of the Listing Rules.

– 2 –

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Code provision A.2.1 of the Corporate Governance Code as set out in Appendix 14 to the Listing Rules states that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Notwithstanding the deviation from code provision A.2.1, the Board believes that Dr. Lui’s extensive experience and knowledge, together with the support of the management, will provide solid and consistent leadership for the Company and its subsidiaries (the ‘‘Group’’). In addition, the vesting of the roles as the chairman and chief executive officer to Dr. Lui would allow efficient and effective implementation of business strategies and decisions, which the Board believes is in the best interest of the business development of the Group.

By order of the Board Wealthking Investments Limited Liu Zhiwei Executive Director and Chairman

Hong Kong SAR, 29 December 2021

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; two non-executive Directors, namely Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Professor He Jia, Mr. Wang Xiaojun and Mr. Chen Yuming.

– 3 –